Your browser doesn't support javascript.
loading
The potential of breast cancer screening in Europe.
Zielonke, Nadine; Kregting, Lindy M; Heijnsdijk, Eveline A M; Veerus, Piret; Heinävaara, Sirpa; McKee, Martin; de Kok, Inge M C M; de Koning, Harry J; van Ravesteyn, Nicolien T.
Afiliação
  • Zielonke N; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Kregting LM; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Heijnsdijk EAM; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Veerus P; National Institute for Health Development, Tallinn, Estonia.
  • Heinävaara S; Finnish Cancer Registry, Helsinki, Finland.
  • McKee M; London School of Hygiene and Tropical Medicine, London, UK.
  • de Kok IMCM; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • de Koning HJ; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • van Ravesteyn NT; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Int J Cancer ; 148(2): 406-418, 2021 01 15.
Article em En | MEDLINE | ID: mdl-32683673
ABSTRACT
Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breast cancer deaths could be prevented if all European countries would biennially screen all women aged 50 to 69 for breast cancer. We calculated the number of breast cancer deaths already prevented due to screening as well as the number of breast cancer deaths which could be additionally prevented if the total examination coverage (organised plus opportunistic) would reach 100%. The calculations are based on total examination coverage in women aged 50 to 69, the annual number of breast cancer deaths for women aged 50 to 74 and the maximal possible mortality reduction from breast cancer, assuming similar effectiveness of organised and opportunistic screening. The total examination coverage ranged from 49% (East), 62% (West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already been prevented due to mammography screening. If all countries would reach 100% examination coverage, 12 434 additional breast cancer deaths could be prevented annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of their breast cancer deaths could be additionally prevented, while in Western Europe it could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illustrates that by further optimising screening coverage, the number of breast cancer deaths in Europe can be lowered substantially.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article